VivoSim Labs, Inc. (VIVS)
NGM · Common · CUSIP 68620A203
Last Price•••.••
Current Yield•.••%
Yield to Call•.••%
Yield to Worst•.••%
Free registration unlocks the quote, yield calculations, price chart and full fundamentals for VIVS and every other security on QuantumOnline.
🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD. Register free to view.

Security Profile

Security Type
Common Stock
CUSIP
68620A203 (prev. 62620A104 )
Market Cap
Micro Cap
Previous Symbol
ONVO (changed 4/2/2025)
Previous Name
Organovo Holdings, Inc.
Business: VivoSim Labs, Inc. designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions.
Notes: Aug. 17, 2020 -- Organovo Holdings, Inc. (the “Company”) (Nasdaq: ONVO) today announced that it filed a certificate of second amendment to its certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of its common stock. The shares underlying the Company’s outstanding options and restricted stock unit awards will also be adjusted accordingly. The reverse stock split will take effect at 5:00 pm (Eastern Time) on August 18, 2020, and the Company’s common stock will open for trading on The Nasdaq Capital Market on August 19, 2020 on a post-split basis. ading of the Company’s common stock on The Nasdaq Capital Market will continue, on a split-adjusted basis, with the opening of the markets on Wednesday, August 19, 2020, under the existing ticker symbol “ONVO” but with a new CUSIP number 68620A203. The reverse stock split reduces the number of shares of the Company’s common stock outstanding from approximately 130.6 million pre-reverse stock split shares to approximately 6.5 million post-reverse stock split shares.

Company Contact

CEO
Keith Murphy
CFO
Thomas P. Hess
Headquarters
11555 Sorrento Valley Rd, Suite 100, San Diego, CA 92121
Phone
858-224-1000
Investor Relations
Taylor J. Crouch · 858-224-1000 · info@vivosim.ai
SEC EDGAR Filings
View filings »